Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 AMG 193 in MTAP-deleted advanced non-small cell lung cancer
NL-OMON60488Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anvumetostat in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Amgen. Primary endpoints: Objective response by investigator in Part 1, Safety and 2 more. Started Apr 2025; status: completed.
02
Drugs
anvumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60488.